Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Quanta Therapeutics

2 clinical trials

1 abstract

Clinical trial
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
Status: Recruiting, Estimated PCD: 2027-04-01
Abstract
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.
Org: Sarah Cannon Research Institute/Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke University Medical Center, Huntsman Cancer Institute, University of Utah,
Clinical trial
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Status: Not yet recruiting, Estimated PCD: 2027-07-01